Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Immunopharmacol Immunotoxicol. 2010 Jun;32(2):339-47. doi: 10.3109/08923970903317445.
The utilization of umbilical cord blood transplantation (UCBT) has been increasing because of the potential advantage of rapid accessibility and the lesser risk of graft-versus-host disease (GVHD), thus allowing less strict HLA matching. IL-28A, also known as IFN-lambda2, has been regarded as a member of a new cytokine family that shares some features with type I interferon (IFN) and was shown to have antiviral activity. The aim of this study was to identify biological activity of IL-28 on cord blood CD4(+) T cells.
In this study, we cultured CD4(+) T cells with IL-28A (20 ng/ml), IL-2 (20 ng/ml) and 5microg/ml MACS Anti-Biotin MACSiBead Particles (bead-to-cell ratio 1:2) for 2 weeks.
Flow cytometry analyses showed that IL-28A cannot be effective on CD25 and Foxp3 expression on cord blood CD4(+) T cells, and it is not involved in proliferation of these cells. Treg suppression assay also showed that this cytokine cannot induce production of regulatory T cells.
We showed that IL-28A is not involved in expression of CD25 and Foxp3 markers and proliferation of CD4(+)CD25(-) T cells, and that our findings also suggest that induction of Foxp3 in T cells activated by anti-CD3/anti-CD28 does not result in the regulatory activity in these cells.
由于脐带血移植（UCBT）具有快速获取和移植物抗宿主病（GVHD）风险较低的潜在优势，因此允许 HLA 匹配要求放宽，其应用越来越多。IL-28A，也称为 IFN-lambda2，被认为是一种新的细胞因子家族的成员，与 I 型干扰素（IFN）具有一些共同特征，并具有抗病毒活性。本研究旨在鉴定 IL-28 对脐血 CD4(+)T 细胞的生物学活性。
在这项研究中，我们用 IL-28A（20ng/ml）、IL-2（20ng/ml）和 5μg/ml MACS Anti-Biotin MACSiBead 微珠（珠-细胞比为 1:2）培养 CD4(+)T 细胞 2 周。
流式细胞术分析表明，IL-28A 不能有效影响脐血 CD4(+)T 细胞 CD25 和 Foxp3 的表达，也不参与这些细胞的增殖。Treg 抑制试验也表明，这种细胞因子不能诱导调节性 T 细胞的产生。
我们表明，IL-28A 不参与 CD4(+)CD25(-)T 细胞 CD25 和 Foxp3 标志物的表达和增殖，并且我们的研究结果还表明，在抗 CD3/抗 CD28 激活的 T 细胞中诱导 Foxp3 不会导致这些细胞的调节活性。
